Literature DB >> 26524267

Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.

S Haji1, J Kiyasu2,3, I Choi1, Y Suehiro1, K Toyoda1, M Tsuda1, A Takamatsu1, Y Nakashima1, H Miyoshi2, M Shiratsuchi4, S Yamasaki5, N Uike1, Y Abe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26524267     DOI： 10.1038/bmt.2015.254

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.

Authors:  Masakatsu Hishizawa; Junya Kanda; Atae Utsunomiya; Shuichi Taniguchi; Tetsuya Eto; Yukiyoshi Moriuchi; Ryuji Tanosaki; Fumio Kawano; Yasushi Miyazaki; Masato Masuda; Koji Nagafuji; Masamichi Hara; Minoko Takanashi; Shunro Kai; Yoshiko Atsuta; Ritsuro Suzuki; Takakazu Kawase; Keitaro Matsuo; Tokiko Nagamura-Inoue; Shunichi Kato; Hisashi Sakamaki; Yasuo Morishima; Jun Okamura; Tatsuo Ichinohe; Takashi Uchiyama
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

2.  Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma.

Authors:  T Okamoto; Y Nishimura; S Yamada; S Yamada; T Itoh; A Mori; K Saheki; M Okada; H Takatsuka; H Wada; A Tamura; Y Fujimori; E Kakishita
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

3.  Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation.

Authors:  Y Ito; T Miyamoto; Y Chong; T Aoki; K Kato; K Akashi; T Kamimura
Journal:  Bone Marrow Transplant       Date:  2013-01-07       Impact factor: 5.483

4.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

Authors:  Ken-ichi Matsuoka; Haesook T Kim; Sean McDonough; Gregory Bascug; Ben Warshauer; John Koreth; Corey Cutler; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

5.  Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.

Authors:  Junya Kanda; Masakatsu Hishizawa; Atae Utsunomiya; Shuichi Taniguchi; Tetsuya Eto; Yukiyoshi Moriuchi; Ryuji Tanosaki; Fumio Kawano; Yasushi Miyazaki; Masato Masuda; Koji Nagafuji; Masamichi Hara; Minoko Takanashi; Shunro Kai; Yoshiko Atsuta; Ritsuro Suzuki; Takakazu Kawase; Keitaro Matsuo; Tokiko Nagamura-Inoue; Shunichi Kato; Hisashi Sakamaki; Yasuo Morishima; Jun Okamura; Tatsuo Ichinohe; Takashi Uchiyama
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

6.  Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials.

Authors:  I Choi; R Tanosaki; N Uike; A Utsunomiya; M Tomonaga; M Harada; T Yamanaka; M Kannagi; J Okamura
Journal:  Bone Marrow Transplant       Date:  2010-04-19       Impact factor: 5.483

7.  Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.

Authors:  Paul J Martin; Ji Pei; Ted Gooley; Claudio Anasetti; Frederick R Appelbaum; Joachim Deeg; John A Hansen; Richard A Nash; Effie W Petersdorf; Rainer Storb; Victor Ghetie; John Schindler; Ellen S Vitetta
Journal:  Biol Blood Marrow Transplant       Date:  2004-08       Impact factor: 5.742

8.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

9.  Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.

Authors:  Takashi Ishida; Tatsuro Jo; Shigeki Takemoto; Hitoshi Suzushima; Kimiharu Uozumi; Kazuhito Yamamoto; Naokuni Uike; Yoshio Saburi; Kisato Nosaka; Atae Utsunomiya; Kensei Tobinai; Hiroshi Fujiwara; Kenji Ishitsuka; Shinichiro Yoshida; Naoya Taira; Yukiyoshi Moriuchi; Kazunori Imada; Toshihiro Miyamoto; Shiro Akinaga; Masao Tomonaga; Ryuzo Ueda
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307
View more
  7 in total

Review 1.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

Review 2.  Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.

Authors:  Shigeo Fuji; Takero Shindo
Journal:  Stem Cell Investig       Date:  2016-10-31

Review 3.  Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?

Authors:  E H Phillips; A Hodson; O Hermine; A Bazarbachi; K Cwynarski
Journal:  Bone Marrow Transplant       Date:  2016-09-12       Impact factor: 5.483

4.  Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.

Authors:  Kenji Ishitsuka; Satoshi Yurimoto; Kouichi Kawamura; Yukie Tsuji; Manabu Iwabuchi; Takeshi Takahashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2017-06-09       Impact factor: 2.319

5.  HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.

Authors:  Makoto Hirosawa; Takehiro Higashi; Atsushi Iwashige; Takahiro Yamaguchi; Junichi Tsukada
Journal:  Ann Hematol       Date:  2016-10-21       Impact factor: 3.673

6.  Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.

Authors:  Makoto Hirosawa; Takahiro Yamaguchi; Aya Tanaka; Yoshihiko Kominato; Takehiro Higashi; Hiroaki Morimoto; Junichi Tsukada
Journal:  Ann Hematol       Date:  2020-01-31       Impact factor: 3.673

7.  Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.

Authors:  Yukie Tsubokura; Atsushi Satake; Masaaki Hotta; Hideaki Yoshimura; Shinya Fujita; Yoshiko Azuma; Takahisa Nakanishi; Aya Nakaya; Tomoki Ito; Kazuyoshi Ishii; Shosaku Nomura
Journal:  Int J Hematol       Date:  2016-08-29       Impact factor: 2.319
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.